Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 7Terminated 3Active not recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myeloid, Chronic-Phase 7Recurrence 5Leukemia, Lymphocytic, Chronic, B-Cell 5Breast Neoplasms 5Multiple Myeloma 4Lymphoma, Large B-Cell, Diffuse 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia 4Carcinoma, Non-Small-Cell Lung 4Burkitt Lymphoma 4Waldenstrom Macroglobulinemia 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Extranodal NK-T-Cell 3Leukemia, Myeloid, Accelerated Phase 3Immunoblastic Lymphadenopathy 3Hodgkin Disease 3Blast Crisis 3Squamous Cell Carcinoma of Head and Neck 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Mycosis Fungoides 2

Interventions

Docetaxel 56Prednisone 36enzalutamide 25Leuprolide 24Magnetic Resonance Spectroscopy 19Abiraterone Acetate 19bicalutamide 17Radiotherapy 15Goserelin 15abiraterone 12acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11olaparib 9Androgen Antagonists 9gallium 68 PSMA-11 8cabazitaxel 8Radiotherapy, Intensity-Modulated 8Metformin 8Ketoconazole 8Gonadotropin-Releasing Hormone 8Cyclophosphamide 8apalutamide 7Doxorubicin 7luprolide acetate gel depot 6cabozantinib 6Radiosurgery 6Estramustine 6Dexamethasone 6Calcitriol 6Biopsy 6pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Prostatic Neoplasms × Dasatinib × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00860158 2018-03-14

Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer

Hoosier Cancer Research Network

Phase 2 Terminated
1 enrolled 3 charts
Genitourinary

Prostatic Neoplasms

NCT00918385 2014-10-29

ARS

Duke University

Phase 2 Terminated
57 enrolled 8 charts
Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡